|
1）Bardeesy N, DePinho R. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12): 897-909. PubMed PMID: 12459728. eng
|
|
|
|
2）Hingorani S, Petricoin E, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003; 4(6): 437-50. PubMed PMID: 14706336. eng
|
|
|
|
|
3）Aguirre A, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adeno-carcinoma. Genes Dev. 2003; 17(24): 3112-26. PubMed PMID: 14681207. Pubmed Central PMCID: PMC305262. eng
|
|
|
|
|
|
4）Hingorani S, Wang L, Multani A, et al. Trp53R172H and KrasG12D cooperate to pro-mote chromosomal instability and widely meta-static pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7(5): 469-83. PubMed PMID: 15894267. eng
|
|
|
|
|
|
5）Bardeesy N, Aguirre A, Chu G, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway con-strain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006; 103(15): 5947-52. PubMed PMID: 16585505. Pubmed Central PMCID: PMC1458678. eng
|
|
|
|
|
|
6）Ijichi H, Chytil A, Gorska A, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006; 20(22): 3147-60. PubMed PMID: 17114585. Pubmed Central PMCID: PMC 1635149. eng
|
|
|
|
|
|
7）Bardeesy N, Cheng K, Berger J, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006; 20(22): 3130-46. PubMed PMID: 17114584. Pubmed Central PMCID: PMC1635148. eng
|
|
|
|
|
|
8）Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007; 11(3): 229-43. PubMed PMID: 17349581. eng
|
|
|
|
|
|
9）Habbe N, Shi G, Meguid RA, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A. 2008; 105(48): 18913-8. PubMed PMID: 19028870. Pubmed Central PMCID: PMC 2596215. eng
|
|
|
|
|
|
10）De La O JP, Emerson LL, Goodman JL, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008; 105(48): 18907-12. PubMed PMID: 19028876. Pubmed Central PMCID: PMC2585942. eng
|
|
|
|
|
|
11）Gidekel Friedlander SY, Chu GC, Snyder EL, et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009; 16(5): 379-89. PubMed PMID: 19878870. eng
|
|
|
|
|
|
12）Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007 11(3): 291-302. PubMed PMID: 17349585. eng
|
|
|
|
|
|
13）Carrière C, Young AL, Gunn JR, et al. Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One. 2011; 6(11): e27725. Epub 2011 Nov 28. PubMed PMID: 22140463; PubMed Central PMCID: PMC3225359
|
|
|
|
|
|
14）Guerra C, Collado M, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011; 19(6): 728-39. PubMed PMID: 21665147. eng
|
|
|
|
|
|
15）Olive K, Jacobetz M, Davidson C, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933): 1457-61. PubMed PMID: 19460966. eng
|
|
|
|
|
|
16）Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010; 28(6): 585-93. PubMed PMID: 20495549. eng
|
|
|
|
|
|
17）Fukuda A, Wang SC, Morris JP, et al. Stat3 and MMP7 contribute to pancreatic ductal adeno-carcinoma initiation and progression. Cancer Cell. 2011; 19(4): 441-55. PubMed PMID: 21481787. Pubmed Central PMCID: PMC 3075548. eng
|
|
|
|
|
|
18）Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neo-plasia and development of pancreatic cancer. Cancer Cell. 2011; 19(4): 456-69. PubMed PMID: 21481788. eng
|
|
|
|
|
|
19）Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024): 1612-6. PubMed PMID: 21436454. Pubmed Central PMCID: PMC3406187. eng
|
|
|
|
|
|
20）Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012; 21(6): 822-35. PubMed PMID: 22698406. eng
|
|
|
|
|
|
21）Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012; 21(6): 836-47. PubMed PMID: 22698407. eng
|
|
|
|
|
|
22）Ijichi H, Chytil A, Gorska AE, et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pan-creatic ductal adenocarcinoma. J Clin Invest. 2011; 121(10): 4106-17. PubMed PMID: 2192 6469. Pubmed Central PMCID: PMC3195452. eng
|
|
|
|
|
|
23）Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3): 418-29. PubMed PMID: 22439937. Pubmed Central PMCID: PMC3371414. eng
|
|
|
|
|
|
24）Maniati E, Bossard M, Cook N, et al. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest. 2011; 121(12): 4685-99. PubMed PMID: 22056382. Pubmed Central PMCID: PMC3225987
|
|
|
|
|
|
25）Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(1): 105-20. PubMed PMID: 22264792. Pubmed Central PMCID: PMC3360958. eng
|
|
|
|
|
|
26）Ying H, Elpek KG, Vinjamoori A, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011; 1(2): 158-69. PubMed PMID: 21984975. Pubmed Central PMCID: PMC3186945. eng
|
|
|
|
|
|
27）Plentz R, Park JS, Rhim AD, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2009; 136(5): 1741-9.e6. PubMed PMID: 19208345. eng
|
|
|
|
|
|
28）Perez-Mancera PA, Rust AG, van der Weyden L, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012; 486(7402): 266-70. PubMed PMID: 22699621. Pubmed Central PMCID: PMC3376394. eng
|
|
|
|
|
|
29）Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149(3): 656-70. PubMed PMID: 22541435. eng
|
|
|
|
|
|
30）Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008; 5(6): e123. PubMed PMID: 18547137. Pubmed Central PMCID: PMC 2504036. eng
|
|
|
|
|
|
31）Kelly KA, Bardeesy N, Anbazhagan R, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008; 5(4): e85. PubMed PMID: 18416599. Pubmed Central PMCID: PMC2292750. eng
|
|
|
|
|
|
32）Ting DT, Lipson D, Paul S, et al. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011; 331(6017): 593-6. PubMed PMID: 21233348. eng
|
|
|
|
|